OnKure Therapeutics, Inc. (OKUR)
3.58
+0.02
(+0.56%)
USD |
NASDAQ |
Sep 04, 16:00
3.40
-0.18
(-5.03%)
After-Hours: 20:00
OnKure Therapeutics Research and Development Expense (Quarterly) : 12.51M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.51M |
| March 31, 2026 | 11.61M |
| December 31, 2025 | 10.62M |
| September 30, 2025 | 11.81M |
| June 30, 2025 | 12.50M |
| March 31, 2025 | 12.89M |
| December 31, 2024 | 36.94M |
| September 30, 2024 | 9.999M |
| June 30, 2024 | 10.64M |
| March 31, 2024 | 8.452M |
| December 31, 2023 | 8.534M |
| September 30, 2023 | 13.58M |
| June 30, 2023 | 14.36M |
| Date | Value |
|---|---|
| March 31, 2023 | 10.95M |
| December 31, 2022 | 10.23M |
| September 30, 2022 | 9.819M |
| June 30, 2022 | 8.11M |
| March 31, 2022 | 9.259M |
| December 31, 2021 | 7.083M |
| September 30, 2021 | 9.305M |
| June 30, 2021 | 6.269M |
| March 31, 2021 | 5.462M |
| December 31, 2020 | 5.108M |
| September 30, 2020 | 4.422M |
| June 30, 2020 | 2.808M |
| March 31, 2020 | 3.569M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 21.96M |
| Theriva Biologics, Inc. | 1.268M |
| Yarrow Bioscience, Inc. | 0.788M |
| Nkarta, Inc. | 26.31M |
| Unicycive Therapeutics, Inc. | 2.788M |